Global Expansion in Clinical Laboratory Molecular Diagnostic Markets for Infectious Diseases: A Comprehensive Guide to Current Trends and Future Forecasts to 2027 - ResearchAndMarkets.com

The "Global Clinical Laboratory Molecular Diagnostic for Infectious Disease Markets" report has been added to ResearchAndMarkets.com's offering.

The clinical laboratory molecular diagnostics sector for infectious diseases is undergoing a significant transformation. A comprehensive research publication, now available, delves into this rapidly growing field with a focus on current strategies, trends, and detailed forecasts spanning from 2023 to 2027.

Industry Dynamics and Trends Shaping the Future of Infectious Disease Diagnostics

Advancements in molecular diagnostics are experiencing a surge, especially in infectious disease testing. Capitalizing on breakthroughs in biotechnology and genomics, the market is expanding with a complex, yet segmented growth evident across multiple diagnostics applications such as transplant medicine, respiratory infections, and more.

Multiplex Testing and Pathogen Evolution: Catalysts for Market Growth

• Emergence of multiplex assays, offering the potential to revolutionize diagnosis and treatment of infectious diseases.
• Understanding the role of pathogen evolution, alongside global factors such as pandemics, which are central to the sector's growth.

Globalization and Climate Change: Twin Forces Influencing Diagnostic Developments

In the face of climate change and globalization, the industry is adapting to new challenges with rapid testing methodologies at the forefront. These developments indicate a shift towards immediate, accurate, and comprehensive diagnostic solutions.

Technological Innovations: Nucleic Acid Testing vs. Immunoassay

Technological advancements continue to fuel competition between nucleic acid testing and immunoassay methods. This dynamic interplay is expected to unfold new opportunities within the global market, with the impact of diagnostics extending towards the goal of eradicating infectious diseases.

Valuable Market Insights and Data for Decision Makers

The detailed report provides extensive information, including a comprehensive list of current United States Medicare Fee Payment Schedules to fine-tune pricing strategies. Market analysis encompasses detailed breakouts for 15 countries and 4 regions, offering crucial insights for stakeholders to make informed investment decisions and valuations.

Key Topics Covered:

1 Market Guides

1.1 Situation Analysis

1.2 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

2.1 Market Definition

2.1.1 Market Size

2.1.2 Currency

2.1.3 Years

2.2 Methodology

2.3 Perspective: Healthcare and the IVD Industry

2.3.1 Global Healthcare Spending

2.3.2 Spending on Diagnostics

2.3.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

3.1 Infectious Disease Pathogens - The Big Picture

3.1.1 Viruses

3.1.2 Bacteria

3.1.3 Fungi

3.1.4 Parasites

3.1.5 Prions

3.1.6 Virulence

3.1.7 Transmission

3.2 The Coronavirus

3.2.1 Severe acute respiratory syndrome (SARS)

3.2.2 Middle East respiratory syndrome (MERS)

3.2.3 COVID-19. The SARS CoV 2 Virus.

3.2.3.1 Signs and symptoms

3.2.3.2 Transmission

3.2.3.3 Diagnosis

3.2.3.4 Prevention

3.2.3.5 Management

3.2.3.6 Prognosis

3.4 HIV - Human Immunodeficiency Virus (AIDS)

3.4.1 Virology

3.4.1.1 Classification

3.4.1.2 Structure and genome

3.4.1.3 Tropism

3.4.1.4 Replication cycle

3.4.1.5 Genetic variability

3.4.2 Diagnosis

3.4.3 Testing

3.4.3.1 Antibody tests

3.4.3.2 Point of Care Tests (POCT)

3.4.3.3 Antigen Tests

3.4.3.4 Nucleic acid-based tests (NAT)

3.4.3.5 Other tests used in HIV treatment

3.5 HBV - Hepatitis B

3.5.1 Virology

3.5.2 Mechanisms

3.5.3 Diagnosis

3.5.4 Market Opportunity Analysis

3.6 HCV - Hepatitis C

3.6.1 Taxonomy

3.6.2 Molecular biology

3.6.3 Replication

3.6.4 Genotypes

3.6.5 Market Opportunity Analysis

3.7 HPV - Human papillomavirus

3.7.1 Virology

3.7.2 Diagnosis

3.7.3 Market Opportunity Analysis

3.8 Influenza

3.8.1 Virology

3.8.1.1 Types of virus

3.8.1.2 Influenzavirus A

3.8.1.3 Influenzavirus B

3.8.1.4 Influenzavirus C

3.8.1.5 Structure, properties, and subtype nomenclature

3.8.1.6 Replication

3.8.2 Testing

3.8.2.1 Advantages/Disadvantages of Molecular Assays

3.8.3 Market Opportunity Analysis

3.9 CTGC - Chlamydia/Gonorhea

3.9.1 Gonorrhea

3.9.2 Chlamydia

3.9.3 Testing

3.9.3.1 Nucleic acid amplification tests (NAATs).

3.9.3.2 Performance of NAAT Tests

3.9.4 Market Opportunity Analysis

3.10 Tuberculosis

3.10.1 Mycobacteria

3.10.2 Diagnosis

3.10.2.1 Active tuberculosis

3.10.2.2 Latent tuberculosis

3.10.3 Epidemiology

3.10.4 Molecular Diagnostic Tests

3.10.5 Market Opportunity Analysis

3.11 MRSA - Methicillin-resistant Staphylococcus aureus

3.11.1 Diagnosis

3.11.2 FDA Approved Molecular Tests

3.11.3 Market Opportunity Analysis

3.12 VRE - Vancomycin-resistant Enterococcus

3.12.1 FDA Approved MDx Tests for VRE

3.12.2 Market Opportunity Analysis

4 Industry Overview

4.1 Players in a Dynamic Market.

4.1.1 Academic Research Lab

4.1.2 Diagnostic Test Developer

4.1.3 Instrumentation Supplier

4.1.4 Chemical/Reagent Supplier

4.1.5 Pathology Supplier

4.1.6 Independent Clinical Laboratory

4.1.7 Public National/regional Laboratory

4.1.8 Hospital Laboratory

4.1.9 Physicians Office Lab (POLS)

4.1.10 Audit Body

4.1.11 Certification Body

4.2 The Clinical Laboratory Market Segments

4.2.1 Traditional Market Segmentation

4.2.2 Laboratory Focus and Segmentation

4.2.3 Segmenting the Syndromic Testing Market

4.3 Industry Structure

4.3.1 Hospital Testing Share

4.3.2 Economies of Scale

4.3.3 Hospital vs. Central Lab

4.3.4 Physician Office Lab's

4.3.5 Physician's and POCT

5 Market Trends

5.1 Factors Driving Growth

5.1.1 New Genotypes Creating New Markets

5.1.2 Aging Population a Boon for All Diagnostics

5.1.3 Developing World Driving ID Dx Growth

5.1.4 Point of Care - Why Centralization is Losing Steam

5.1.5 Self Testing

5.1.6 The Need for Speed

5.1.7 The COVID Pandemic

5.2 Factors Limiting Growth

5.2.1 Lower Costs

5.2.2 Infectious Disease is Declining

5.2.3 Wellness Hurts

5.2.4 Economic Growth Improves Living Standards

5.3 Instrumentation, Automation and Diagnostic Trends

5.3.1 Traditional Automation and Centralization

5.3.2 The New Automation, Decentralization and Point Of Care

5.3.3 Instruments Key to Market Share

5.3.4 Bioinformatics Plays a Role

5.3.5 PCR Takes Command

5.3.6 Next Generation Sequencing Fuels a Revolution

5.3.7 NGS Impact on Pricing

5.3.8 Whole Genome Sequencing, A Brave New World

5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

6.1 Recent Developments - Importance and How to Use This Section

6.1.1 Importance of These Developments

6.1.2 How to Use This Section

6.2 Spindiag Seeks Investors for Rapid PCR System

6.3 Sorrento Therapeutics Nabs Contract for Dx Platform

6.4 Kephera Planning Menu of Infectious Disease Tests

6.5 Oxford Nanopore and BioMerieux to Develop IDDx

6.6 SD Biosensor Eyes Global Expansion

6.7 Selux Dx Next Gen Phenotyping Gets FDA Clearance

6.8 Takara Developing High-Throughput Multiplex Panels

6.9 BioGX Debuts New Point-of-Care Molecular Testing System

6.10 Nanopath MDx Platform Providing 15-Minute Results

6.11 ProtonDx Commercializing Rapid MDx Instrument

6.12 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform

6.13 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays

6.14 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS

6.15 Accelerate Diagnostics Anticipates Growth

6.16 Growth of Decentralized Testing Expected to Continue

6.17 Lumos Diagnostics Expanding Test Portfolio

6.18 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

6.19 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients

6.20 Accelerated Development of CRISPR as a Diagnostic Platform

6.21 Lab-on-a-Chip Infection Test Threatens Clinical Laboratory Role

7 Key Companies and Competitive Analysis

7.1 Abbott Laboratories

7.2 Beckman Coulter Diagnostics

7.3 Becton, Dickinson and Company

7.4 bioMerieux Diagnostics

7.5 Bio-Rad Laboratories, Inc.

7.6 Cepheid (Danaher)

7.7 Hologic

7.8 Ortho Clinical Diagnostics

7.9 Perkin Elmer.

7.10 Qiagen

7.11 Roche Molecular Diagnostics

7.12 Siemens Healthineers

7.13 Thermo Fisher Scientific Inc.

8 The Global Market for Clinical Laboratory MDx Infectious Disease

8.1 Global Market Overview by Country

8.2 Global Market by Application - Overview

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

9.1 Respiratory

9.2 Blood Borne Virus

9.3 Transplant

9.4 Hospital Acquired Infections

9.5 Reproductive Health

9.6 C19 Singleplex

9.7 Other

10 Appendices

10.1 United States Medicare System: Clinical Laboratory Fees Schedule

10.2 The Most Used IVD Assays

10.3 The Highest Grossing Assays

For more information about this report visit https://www.researchandmarkets.com/r/creve2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430644163/en/